Jinhai Medical Technology Limited

SEHK:2225 Stock Report

Market Cap: HK$8.8b

Jinhai Medical Technology Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Jinhai Medical Technology.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Professional Services earnings growth12.7%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Jinhai Medical Technology Limited's (HKG:2225) Share Price Is Still Matching Investor Opinion Despite 27% Slump

Dec 16
Jinhai Medical Technology Limited's (HKG:2225) Share Price Is Still Matching Investor Opinion Despite 27% Slump

Jinhai Medical Technology (HKG:2225) Has Debt But No Earnings; Should You Worry?

Nov 05
Jinhai Medical Technology (HKG:2225) Has Debt But No Earnings; Should You Worry?

Why We're Not Concerned About Jinhai Medical Technology Limited's (HKG:2225) Share Price

Oct 06
Why We're Not Concerned About Jinhai Medical Technology Limited's (HKG:2225) Share Price

The CEO Of Jinhai Medical Technology Limited (HKG:2225) Might See A Pay Rise On The Horizon

Jun 19
The CEO Of Jinhai Medical Technology Limited (HKG:2225) Might See A Pay Rise On The Horizon

Investors Appear Satisfied With Jinhai Medical Technology Limited's (HKG:2225) Prospects As Shares Rocket 26%

May 13
Investors Appear Satisfied With Jinhai Medical Technology Limited's (HKG:2225) Prospects As Shares Rocket 26%

Subdued Growth No Barrier To Jinhai Medical Technology Limited (HKG:2225) With Shares Advancing 31%

Mar 17
Subdued Growth No Barrier To Jinhai Medical Technology Limited (HKG:2225) With Shares Advancing 31%

What Jinhai International Group Holdings Limited's (HKG:2225) 50% Share Price Gain Is Not Telling You

Jan 31
What Jinhai International Group Holdings Limited's (HKG:2225) 50% Share Price Gain Is Not Telling You

Here's What's Concerning About Jinhai International Group Holdings' (HKG:2225) Returns On Capital

Jun 06
Here's What's Concerning About Jinhai International Group Holdings' (HKG:2225) Returns On Capital

Be Wary Of Jinhai International Group Holdings (HKG:2225) And Its Returns On Capital

Mar 07
Be Wary Of Jinhai International Group Holdings (HKG:2225) And Its Returns On Capital

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Jinhai Medical Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:2225 - Analysts future estimates and past financials data (SGD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/202460-10-20N/A
3/31/202453-7-2-1N/A
12/31/202346-3-3-2N/A
9/30/202333-2-10N/A
6/30/202320012N/A
3/31/202321023N/A
12/31/202222034N/A
9/30/202225023N/A
6/30/202227022N/A
3/31/202224023N/A
12/31/202122033N/A
9/30/202120033N/A
6/30/202118133N/A
3/31/202120155N/A
12/31/202022177N/A
9/30/202031188N/A
6/30/202040099N/A
3/31/202046089N/A
12/31/201952-178N/A
9/30/201951-167N/A
6/30/201951-255N/A
3/31/201949-311N/A
12/31/201847-4-3-2N/A
9/30/201846-2-2-2N/A
6/30/201844-1-2-2N/A
3/31/2018441N/A-2N/A
12/31/2017442N/A-1N/A
12/31/2016457N/A7N/A
12/31/2015466N/A10N/A
12/31/2014454N/A9N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 2225's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if 2225's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 2225's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 2225's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 2225's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 2225's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 01:19
End of Day Share Price 2024/12/18 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jinhai Medical Technology Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution